Blackstone (NYSE: BX) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (‘Reata’), a clinical-stage biopharmaceutical company, today announced that funds managed by Blackstone Life Sciences (‘BXLS’) will lead a $350 million royalty and equity investment in Reata to fund the development and potential commercialization of bardoxolone methyl (‘bardoxolone’), an investigational once-daily oral therapy being studied for chronic kidney disease (‘CKD’) in Alport syndrome, autosomal dominant polycystic kidney disease (‘ADPKD’), and other associated potential future indications. These are severe, life-threatening diseases with few or no effective therapies approved by the U.S. Food and Drug Administration (‘FDA’).
Read the full article: Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350M Strategic Investment //
Source: https://www.globenewswire.com/news-release/2020/06/11/2046801/0/en/Reata-Pharmaceuticals-Inc-and-Blackstone-Life-Sciences-Announce-350-Million-Strategic-Investment.html